Novo Nordisk wins big on strong US dollar The sharply rising US dollar exchange rate compared to the Danish krone is very lucrative for Danish firms. Novo Nordisk is the clear winner, but many other healthcare companies also stand to benefit. Photo: Jacob Gronholt-Pedersen/REUTERS / X04292 by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen Published: 03.12.21 at 10:30 Danish business, with pharmaceutical flagship Novo Nordisk at the forefront, is winning big on a dramatic rise in the US dollar exchange rate. Already a subscriber? Log in. Read the whole article Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial. Access all locked articles Receive our daily newsletters Access our app First name: Last name: E-mail address: Password: I accept the terms and conditions An error has occured. Please try again later. Create trial Get full access for you and your coworkers. Start a free company trial today More from MedWatch More countries back EU Commission investigation into potential Oticon sale Competition authorities in 13 countries have now asked the EU Commission to examine Demant’s potential sale of Oticon Medical to Cochlear. Nobel Prize winner: "Good research is driven by curiosity" The best research comes from curiosity, not personal ambition, says one of the three recipients of Nobel Prize in Chemistry. FDA ruling to trigger royalty payments for Novo Nordisk The FDA has just approved a drug licensed by Forma Therapeutics, which Novo Nordisk acquired in September. Royalties from the newly approved cancer treatment will total 13-35% of sales. USD 1.6bn investment to ensure supplies of sought-after Novo Nordisk drug After a challenging launch of Wegovy, where Novo Nordisk couldn’t keep up with skyrocketing demand, the pharmaceutical firm is making a large investment to increase production. Coloplast deputy chair spends USD 7m on shares in firm Niels Peter Louis-Hansen has bought 56,770 shares in the medtech firm through his company, Aage og Johanne Louis-Hansen. Print Print Increase text size Increase text size Decrease text size Decrease text size Further reading Analyst sees positive elements in new Ambu strategy, though guidance disappoints USD 1.6bn investment to ensure supplies of sought-after Novo Nordisk drug FDA ruling to trigger royalty payments for Novo Nordisk More countries back EU Commission investigation into potential Oticon sale Novo Nordisk Foundation issues grant to support RNA vaccine development in Denmark Related articles Analyst on Novo stock: The risk of disappointments is bigger than the chance of surprises Sonova loses Veterans Affairs market shares Ambu has replaced its duodenoscopes the world over: "We have the product of choice"